A population analysis of weight-related differences in lopinavir pharmacokinetics and possible consequences for protease inhibitor-naive and -experienced patients.

Marion Bouillon-Pichault; Vincent Jullien; Christophe Piketty; Jean-Paul Viard; Jean-Pierre Morini; Stéphanie Chhun; Anne Krivine; Dominique Salmon; Nicolas Dupin; Laurence Weiss; Olivier Lortholary; Gérard Pons; Odile Launay; Jean-Marc Treluyer

doi:10.3851/IMP1414

Publisher Website

A population analysis of weight-related differences in lopinavir pharmacokinetics and possible consequences for protease inhibitor-naive and -experienced patients.

Authors

Bouillon-Pichault, Marion
Jullien, Vincent
Piketty, Christophe
Viard, Jean-Paul
Morini, Jean-Pierre
Chhun, Stéphanie
Krivine, Anne
Salmon, Dominique
Dupin, Nicolas
Weiss, Laurence
Lortholary, Olivier
Pons, Gérard
Launay, Odile
Jean-Marc Treluyer

Type

Published Article

Journal

Diabetes Care

Publisher

American Diabetes Association

Publication Date

2009

Volume

14

Issue

7

Pages

923–929

Identifiers

DOI: 10.3851/IMP1414

PMID: 19918096

Source

USPC - SET - SVS

License

Unknown

Abstract

These results support lopinavir therapeutic drug monitoring and the use of higher lopinavir doses for PI-pretreated patients.

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. This record was last updated on 10/03/2017 and may not reflect the most current and accurate biomedical/scientific data available from NLM. The corresponding record at NLM can be accessed at https://www.ncbi.nlm.nih.gov/pubmed/19918096

Report this publication

Statistics

Seen <100 times